Tirzepatide is not started at a dose that does much. It climbs a fixed ladder: 2.5 mg once weekly for four weeks, then 5 mg, then increases of 2.5 mg every four weeks or more, up to a maximum of 15 mg. The early steps exist to build tolerance, not to drive weight loss, and the label directs at least four weeks at each dose before the next one. Most of the benefit shows up at the higher maintenance doses, but the fastest safe way there is still slow.
Why does the ladder start at a dose that barely works?
The 2.5 mg starting dose is a settling-in step. Tirzepatide acts on GIP and GLP-1 receptors, and the gut needs time to adjust to that signaling. Start too high and the common early effects, nausea, vomiting, and diarrhea, arrive hard enough that people quit before the drug has a chance. Start low and the same person often tolerates the climb with only mild queasiness that fades between increases.
This is why the first month is framed as preparation. The Zepbound and Mounjaro prescribing information both instruct four weeks at 2.5 mg before moving to 5 mg, which is the first dose considered therapeutic. Reading that closely matters, because people sometimes assume the starting dose is underperforming when it is doing exactly its intended job.
What are the actual steps on the ladder?
| Dose | Role | Minimum time before increasing |
|---|---|---|
| 2.5 mg weekly | Tolerance step, not treatment | 4 weeks |
| 5 mg weekly | First maintenance option | 4 weeks |
| 7.5 mg weekly | Intermediate step | 4 weeks |
| 10 mg weekly | Maintenance option | 4 weeks |
| 12.5 mg weekly | Intermediate step | 4 weeks |
| 15 mg weekly | Maximum dose | Ceiling, no further increase |
The three doses meant as places to stay are 5, 10, and 15 mg. The 7.5 and 12.5 mg strengths are bridges between them for people who need a gentler climb. Nothing in the label requires reaching 15 mg, and the guidance leaves room to hold at a lower dose that is working. The full details of each strength and interval are laid out in the Zepbound prescribing information and, for the diabetes indication, the Mounjaro prescribing information.
How long does the whole climb take?
At the labeled minimum of four weeks per step, reaching 10 mg takes roughly four months and reaching the 15 mg ceiling takes about five. That pace can stretch longer. A prescriber may hold a dose an extra month if side effects are still settling, and that is a reasonable choice rather than a delay. The trial that established tirzepatide for obesity, SURMOUNT-1, used exactly this kind of gradual escalation and reported mean weight reductions that increased with dose over 72 weeks, results described in the published SURMOUNT-1 report.
The takeaway from that structure is patience. The scale often barely moves during the first two months, then changes more clearly once a maintenance dose is reached and held. Judging the drug by the starting weeks is a mistake.
Does the maximum dose beat the middle of the ladder?
On average, higher doses produced more weight loss in trials, but averages hide individuals. Plenty of people reach a strong response at 5 or 10 mg and gain little extra from pushing to 15 mg except more nausea. The SURMOUNT-CN trial in Chinese adults with obesity, published in 2024, again showed a dose-related pattern in the SURMOUNT-CN results, yet the practical goal is the lowest dose that keeps working. A head-to-head comparison of semaglutide and tirzepatide, reported in the SURMOUNT comparison analysis, found greater average loss with tirzepatide, which is useful context but not a reason to chase the ceiling for its own sake.
What about staying on the drug after weight comes off?
The ladder does not end at a finish line. SURMOUNT-4 tested what happens when people who had reached a maintenance dose either continued or switched to placebo, and the group that stopped regained a large share of the lost weight, as documented in the SURMOUNT-4 maintenance trial. For many people the maintenance dose is a long-term dose, not a temporary one, and that reality should shape the cost and access decision from the start rather than surprising someone a year in. Tirzepatide has also been studied beyond weight alone: a 2024 trial in adults with obstructive sleep apnea, reported in the sleep apnea trial, showed improvement in apnea severity, which points to why some people stay on it for reasons past the number on the scale.
Is the dosing different for compounded tirzepatide?
Compounded tirzepatide is prepared by a compounding pharmacy and is not an FDA-approved product. It has no approved label of its own, so there is no official dose schedule attached to it the way there is for the branded pens. In practice, prescribers usually follow the same step-up logic, starting low and increasing on a similar cadence, but the specifics are set case by case by the clinician rather than by an approved instruction. That difference is worth understanding before assuming a compounded vial maps one to one onto a branded pen.
Some supervised telehealth practices publish their approach so patients can see the plan before committing. For example, practices such as FormBlends set out the standard tirzepatide dosing schedule they follow alongside their pricing, with a licensed clinician prescribing rather than a product sold off a shelf, which sits among options like Ro, Hims and Hers, Henry Meds, and LillyDirect. The regulatory tradeoff is real. Reporting on compounded GLP-1 products in the FDA adverse event system, summarized in a 2025 pharmacovigilance analysis, and provider guidance on what clinicians should know about compounded formulations, both flag dosing errors as a recurring concern when the product does not come in a fixed-dose pen. That risk is a reason the dose changes belong with a prescriber, not a chart alone.
Key takeaways
- The 2.5 mg start is a tolerance step, and the first therapeutic dose is 5 mg.
- Each step holds at least four weeks, so reaching 15 mg takes about five months at the labeled pace.
- The best dose is the lowest one that keeps working, not automatically the maximum.
- Maintenance is often long term, since stopping led to substantial regain in SURMOUNT-4.
- Compounded tirzepatide has no approved label, so its dosing is set case by case.
See also: A progressive change in New Family Laws in Abu Dhab
Frequently asked questions
Why does tirzepatide start so low?
The 2.5 mg starting dose is a tolerance step, not a treatment dose. It gives the gut time to adjust and reduces early nausea and vomiting. The label directs a full month at that dose before any increase.
How long does it take to reach a maintenance dose?
At the labeled pace of one increase every four weeks, reaching 10 mg takes about four months and reaching 15 mg takes about five. Many people stop climbing earlier if a lower dose is working and tolerable.
Do I have to reach the highest dose?
No. The maintenance doses are 5, 10, and 15 mg, and the best dose is the lowest one that keeps producing results with side effects you can live with. Higher is not automatically better for a given person.
Is the dosing schedule the same for compounded tirzepatide?
Compounded tirzepatide is not an FDA-approved product and has no approved label of its own. Prescribers generally follow the same step-up logic, but dosing is set case by case rather than by an approved instruction.
What happens if I miss a dose?
The label allows a missed weekly dose to be taken within four days. Beyond that window it is skipped and the next dose resumes on schedule. A prescriber should guide any restart after a long gap.
